Belite Bio, Inc (BLTE) Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease Transcript [Seeking Alpha]
Belite Bio, Inc - American Depositary Shares (BLTE)
Company Research
Source: Seeking Alpha
Company Participants Nathan L. Mata - Chief Scientific Officer Hendrik Scholl - Chief Medical Officer Michel Michaelides Yu-Hsin Lin - Chairman of the Board of Directors & CEO Conference Call Participants Ruifang Sui Leopold Schmetterer Marc Goodman - Leerink Partners LLC, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Yi Chen - H.C. Wainwright & Co, LLC, Research Division Bruce Jackson - The Benchmark Company, LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for joining us, and welcome to Belite Bio's Phase III DRAGON Topline Results Conference Call. [Operator Instructions] I will now hand the conference over to Nathan Mata. Please go ahead. Nathan L. Mata Chief Scientific Officer Welcome, everyone, to the webcast presentation of topline data from our 2-year Phase III trial of Tinlarebant in Stargardt disease. This pivotal trial is known as the DRAGON study and is the largest interventiona
Show less
Read more
Impact Snapshot
Event Time:
BLTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLTE alerts
High impacting Belite Bio, Inc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BLTE
News
- Has Belite Bio's 134% 2025 Surge Fully Reflected Its DCF and Book Value Picture [Yahoo! Finance]Yahoo! Finance
- Belite Bio (NASDAQ:BLTE) was given a new $187.00 price target on by analysts at BTIG Research.MarketBeat
- Belite Bio (NASDAQ:BLTE) had its "buy" rating reaffirmed by analysts at Benchmark Co..MarketBeat
- Belite Bio (NASDAQ:BLTE) was upgraded by analysts at Mizuho from a "hold" rating to a "strong-buy" rating.MarketBeat
- Belite Bio (NASDAQ:BLTE) was given a new $200.00 price target on by analysts at Maxim Group.MarketBeat
BLTE
Earnings
- 11/10/25 - Miss
BLTE
Sec Filings
- 12/2/25 - Form 424B5
- 12/2/25 - Form 6-K
- 12/1/25 - Form 424B5
- BLTE's page on the SEC website